Description: Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO, PROBUPHINE, Advaxis Family of Products, Ember Family of Products, NeurAxon Family of Products, Antibe Family of Products, Blood Factor Products and VEWS Vascular Early Warning System. In addition, the Company also has a portfolio of branded consumer health products, including Neuragen, Flat Tummy Tea, FOCUSFactor, FLEXISEQ, SEQuaderma, HandMD, UrgentRx, Laboratoire Dr. Renaud, Premiology and Pro-Derm.
Home Page: www.gud-knight.com
GUD Technical Analysis
3400 De Maisonneuve Boulevard West
Montreal,
QC
H3Z 3B8
Canada
Phone:
514 484 4483
Officers
| Name | Title |
|---|---|
| Mr. Jonathan Ross Goodman B.A., BA, L.L.B., LLB, M.B.A., MBA | Exec. Chairman |
| Ms. Samira Sakhia BCom, CA, CPA, MBA | Pres, CEO & Director |
| Mr. Arvind Utchanah | Chief Financial Officer |
| Ms. Amal Khouri B.Sc., M.B.A. | Chief Bus. Officer |
| Mr. Jeff Martens | Global VP Commercial |
| Mr. Leopoldo Bosano | Vice-Pres of Manufacturing & Operations |
| Ms. Daniela Marino | Global VP of Legal & Compliance |
| Ms. Susan Caroline Emblem | Global VP of HR |
| Ms. Jody Engel | Sr. Director of Bus. Devel. |
Exchange: TO
Country: CA : Canada
Currency: Canadian Dollar (C$)
| Forward PE: | 14.4928 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7028 |
| Price-to-Sales TTM: | 2.2186 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 660 |